Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Multiple Myeloma
I/II
Dholaria, Bhagirathbhai
NCT03288493
VICCCTTP19143

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: